Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CASSART PHARMA from Silly, company number BE0780539006, closed financial year 2025 with a result of € 62,643 after tax. For that financial year CASSART PHARMA recorded a gross margin of € 137,032 and equity of € 292,691. Compared with financial year 2024, the result moved from € 228,963 to € 62,643. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 292,691
▲ 26% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 62,643
▼ 73% vs 2024
Profit after tax over the fiscal year.
€ 11,581
▲ 101% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1,666 paid out
3 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 1 million
▼ 5% vs 2024
€ 61,262 is repaid this year. At this pace the long-term loan is gone in ≈ 17 years.
€ 1,349
▼ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 3,882
▼ 47% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,443 | € 15,803 | € 134,964 | € 137,032 | ▲ 2% |
| Profit after taxes | € -5,147 | € 8,164 | € 228,963 | € 62,643 | ▼ 73% |
| Equity | € -2,147 | € 4,417 | € 231,714 | € 292,691 | ▲ 26% |
| Total debts | € 20,149 | € 1,479,609 | € 1,459,405 | € 1,386,156 | ▼ 5% |
| Cash | € 4,986 | € 13,342 | € 5,774 | € 11,581 | ▲ 101% |
| Retained profit | € -5,147 | € 1,417 | € 228,714 | € 289,691 | ▲ 27% |
| Dividend | € 0 | € 1,600 | € 1,666 | € 1,666 | |
| Bank debt | € 0 | € 1,150,000 | € 1,093,770 | € 1,035,010 | ▼ 5% |
| Balance sheet total | € 18,003 | € 1,484,026 | € 1,691,119 | € 1,678,847 | ▼ 1% |
Key figures of CASSART PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CASSART PHARMA?
What happened at CASSART PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 62,643 (▼ 73% vs 2024). Source: NBB ↗
- André Peltzer Marc became a director. NBB
- New establishment in Silly. KBO
- Start of the company according to the CBE. KBO
In short
From € 5,147 loss in 2022 to € 62,643 profit in 2025.
Paid € 36,083 in corporate taxes since 2022.
Best year ever: 2024, with € 228,963 profit.
Paid out € 4,932 in dividends to the owners in total.
Management
Behind CASSART PHARMA are Pierre Cassart François and André Peltzer Marc.
Directors
According to the 2025 annual accounts
Pierre Cassart François
Director
André Peltzer Marc
Director
since 2026
Establishments
Establishment units
Physical locations of this company
Rue de l'Eglise(Fouleng) 31
7830 Silly
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0780.539.006
- VAT number
- BE 0780.539.006
- Registered office
- Rue de l'Eglise(Fouleng) 31, 7830 Silly
- Names & denominations
- CASSART PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 17 January 2022
- Peppol
- Active · Active since 15 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten